NSE Healthcare Drug Manufacturers - Specialty & Generic APLLTD.NS

Alembic Pharmaceuticals Limited

$ 763.90 1.89 %

Alembic Pharmaceuticals Limited is a pharmaceutical firm that develops, manufactures, and markets medicinal products both domestically in India and across international markets. Its offerings encompass active pharmaceutical ingredients (APIs) and a wide array of formulations. The company provides both proprietary (branded) and generic medications, addressing numerous therapeutic needs such as cardiovascular health, women's health, gastrointestinal issues, eye and skin conditions, kidney/urinary tract disorders, orthopedic ailments, anti-infective treatments, remedies for cold and cough, and anti-diabetic management. Furthermore, the company engages in the export of its diverse product portfolio. Founded in 1907, Alembic Pharmaceuticals Limited maintains its main office in Vadodara, India.

CEO: Chirayu Ramanbhai Amin - https://alembicpharmaceuticals.com

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

-

Recommandation

-

DCF

$ 850.42

Loading data...

APLLTD.NS vs S&P500

Loading data...

No data available.

Quick ratio

0.79

indicates that the company may have difficulty covering its short-term debts with its readily available assets.

P/E ratio

22.27

is considered reasonable, suggesting that the company has a valuation in line with its current profits.

EPS

34.30

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

12.63 %

reflects reasonable profitability, showing good use of equity.

ROIC

19.16 %

generates a return higher than the cost of its capital, thereby creating value for its investors.

WACC

6.07

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.25

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

8.58

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

32.04 %

indicates that the company is retaining a large portion of its profits to reinvest in growth

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
4 indicates moderate financial health
Altman score
4.31 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.08 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.16 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.